Indication
CD79A gene mutation
1 clinical trial
5 drugs
Clinical trial
A Single Arm, Multi-center, Phase II Clinical Trial of Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma and CD79A/CD79B Genetic AbnormalityStatus: Recruiting, Estimated PCD: 2023-12-25
Drug
VarlilumabDrug
ZanubrutinibDrug
cyclophosphamideDrug
EpirubicinDrug
R-CHOP